Lack of Durable Improvements in β-Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The Restoring Insulin Secretion (RISE) Adult Medication Study compared pharmacological approaches targeted to improve β-cell function in individuals with impaired glucose tolerance (IGT) or treatment-naive type 2 diabetes of <12 months duration. RESEARCH DESIGN AND METHODS: A total of 267 adults with IGT (n = 197, 74%) or recently diagnosed type 2 diabetes (n = 70, 26%) were studied. Participants were randomized to receive 12 months of metformin alone, 3 months of insulin glargine with a target fasting glucose <5 mmol/L followed by 9 months of metformin, 12 months of liraglutide combined with metformin, or 12 months of placebo. β-Cell function was assessed using hyperglycemic clamps at baseline, 12 months (on treatment), and 15 months (3 months off treatment). The primary outcome was β-cell function at 15 months compared with baseline. RESULTS: All three active treatments produced on-treatment reductions in weight and improvements in HbA1c compared with placebo; the greatest reductions were seen in the liraglutide plus metformin group. At 12 months, glucose-stimulated C-peptide responses improved in the three active treatment groups and were greatest in the liraglutide plus metformin group, but the arginine-stimulated incremental C-peptide response was reduced in the liraglutide plus metformin group. Despite on-treatment benefits, 3 months after treatment withdrawal there were no sustained improvements in β-cell function in any treatment group. CONCLUSIONS: In adults with IGT or recently diagnosed type 2 diabetes, interventions that improved β-cell function during active treatment failed to produce persistent benefits after treatment withdrawal. These observations suggest that continued intervention may be required to alter the progressive β-cell dysfunction in IGT or early type 2 diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Affected young people have a more rapid deterioration in blood glucose levels, an attenuated response to diabetes medication, and more rapid development of diabetes complications (269 -273).”
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
An Efficient Method of Estimating Seemingly Unrelated Regressions and Tests for Aggregation Bias
Zellner, A. (1962) · Journal of the American Statistical Association · doi:10.1080/01621459.1962.10480664 · Cited by 8,401
Mechanisms linking obesity to insulin resistance and type 2 diabetes
Kahn, S. E., Hull, R. L., & Utzschneider, K. M. (2006) · Nature · doi:10.1038/nature05482 · Cited by 5,448 · cited 1×
“Similarly, in established diabetes, progressive loss of glycemic control arises from ongoing deterioration of b-cell function (2).”
BackgroundSelf-citationWeyer, C., Bogardus, C., Mott, D. M., & Pratley, R. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7231 · Cited by 1,940
The Finnish Diabetes Prevention Study (DPS)
Lindström, J., Louheranta, A., Mannelin, M., Rastas, M., Salminen, V., Eriksson, J., Uusitupa, M., Tuomilehto, J., & for the Finnish Diabetes Prevention Study Group (2003) · Diabetes Care · doi:10.2337/diacare.26.12.3230 · Cited by 1,848
Basal insulin and cardiovascular and other outcomes in dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636
The Generalization of Student's Ratio
Hotelling, H. (1931) · The Annals of Mathematical Statistics · doi:10.1214/aoms/1177732979 · Cited by 1,492
Buchanan, T. A., Xiang, A. H., Peters, R. K., Kjos, S. L., Marroquin, A., Goico, J., Ochoa, C., Tan, S., Berkowitz, K., Hodis, H. N., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.9.2796 · Cited by 1,339
Self-citation(2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00291-0 · Cited by 1,029
le Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30069-7 · Cited by 850
Cited by
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048
Pancreatic β-cells in type 1 and type 2 diabetes mellitus: different pathways to failure
Eizirik, D. L., Pasquali, L., & Cnop, M. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0355-7 · Cited by 854
Long-term complications in youth-onset type 2 diabetes
TODAY Study Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100165 · Cited by 546
Diagnosis and Management of Prediabetes: A Review
Echouffo-Tcheugui, J. B., Perreault, L., Ji, L., & Dagogo-Jack, S. (2023) · JAMA · doi:10.1001/jama.2023.4063 · Cited by 473
Heise, T., Mari, A., DeVries, J. H., Urva, S., Li, J., Pratt, E. J., Coskun, T., Thomas, M. K., Mather, K. J., Haupt, A., et al. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00085-7 · Cited by 268
Self-citationBeta-cell failure in type 2 diabetes: mechanisms, markers, and clinical implications
Wysham, C., & Shubrook, J. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1771047 · Cited by 193
Bjornstad, P., Dart, A. B., Donaghue, K. C., Dost, A., Feldman, E. L., Tan, G. S. W., Wadwa, R. P., Zabeen, B., & Marcovecchio, M. L. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13444 · Cited by 195
Youth-onset type 2 diabetes mellitus: an urgent challenge
Bjornstad, P., Chao, L. C., Cree‐Green, M., Dart, A. B., King, M., Looker, H. C., Magliano, D. J., Nadeau, K. J., Pinhas‐Hamiel, O., SHAH, A. S., et al. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00645-1 · Cited by 169
Self-citationZhu, D., Li, X., Ma, J., Zeng, J., Gan, S., Dong, X., Yang, J., Lin, X., Cai, H., Song, W., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01802-6 · Cited by 97
The RISE Consortium* (2019) · Diabetes · doi:10.2337/db19-0299 · Cited by 72
“Joint models for b-cell response and M/I were fit simultaneously using seemingly unrelated regression techniques (11–13), which provide a 2-DF x2 test of the treatment arm difference in the joint values of b-cell response and M/I between treatment groups within study.”
MethodResultInfluentialType 2 diabetes: one disease, many pathways
Ha, J., & Sherman, A. (2020) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00512.2019 · Cited by 70
Metformin Should Not Be Used to Treat Prediabetes
Davidson, M. B. (2020) · Diabetes Care · doi:10.2337/dc19-2221 · Cited by 53
“tes were not fundamentally altered by these drug treatments (42,43), which explains the lack of any long-term ef-”
BackgroundSam, S., Edelstein, S. L., Arslanian, S. A., Barengolts, E., Buchanan, T. A., Caprio, S., Ehrmann, D. A., Hannon, T. S., Tjaden, A. H., Kahn, S. E., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0027 · Cited by 50
“Previous cross-sectional, observational, and randomized trials have suggested that youth have a more accelerated progression to type 2 diabetes and earlier development of diabetes complications compared with adults (8,10,11,21).”
BackgroundMethodResultInfluentialSelf-citationArslanian, S. A., El ghormli, L., Kim, J. Y., Tjaden, A. H., Barengolts, E., Caprio, S., Hannon, T. S., Mather, K. J., Nadeau, K. J., Utzschneider, K. M., et al. (2021) · Diabetes Care · doi:10.2337/dc20-2134 · Cited by 45
Self-citationA human antibody against pathologic IAPP aggregates protects beta cells in type 2 diabetes models
Wirth, F., Heitz, F. D., Seeger, C., Combaluzier, I., Breu, K., Denroche, H. C., Thévenet, J., Osto, M., Arosio, P., Kerr-Conte, J. A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41986-0 · Cited by 53
Functional loss of pancreatic islets in type 2 diabetes: How can we halt it?
Marrano, N., Biondi, G., Cignarelli, A., Perrini, S., Laviola, L., Giorgino, F., & Natalicchio, A. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154304 · Cited by 41
Utzschneider, K. M., Tripputi, M. T., Kozedub, A., Barengolts, E., Caprio, S., Cree‐Green, M., Edelstein, S. L., ghormli, L. K. E., Hannon, T. S., Mather, K. J., et al. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108948 · Cited by 39
Self-citationIngersen, A., Schmücker, M., Alexandersen, C., Graungaard, B., Thorngreen, T., Borch, J., Holst, J. J., Helge, J. W., & Dela, F. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad326 · Cited by 39
Qin, N., Zhou, Z., Zhao, W., Zou, K., Shi, W., Yu, C., Liu, X., Dong, Z.-H., Mao, Y., Liu, X., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.637781 · Cited by 35
“Compared with fresh embryo transfer, FET cycles appear to show better obstetric and fetal outcomes, such as lower risks of low birth weight, small for gestational age and extremely preterm birth (Sha et al., 2018; Gu et al., 2019; Roque et al., 2019).”
BackgroundYouth-onset Type 2 Diabetes: An Overview of Pathophysiology, Prognosis, Prevention and Management
Titmuss, A., Korula, S., Wicklow, B. A., & Nadeau, K. J. (2024) · Current Diabetes Reports · doi:10.1007/s11892-024-01546-2 · Cited by 46
“There is also an urgent need to develop new models of care that more effectively engage youth with T2D and holistically improve mental health and wellbeing.”
BackgroundSelf-citationDavidson, M. B. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109219 · Cited by 37
Nadeau, K. J., Mayer‐Davis, E. J., Gubitosi‐Klug, R., Zeitler, P. S., Kahn, S. E., Dabelea, D., & SEARCH, T. (2025) · Diabetes Care · doi:10.2337/dc25-0001 · Cited by 39
Self-citationNew Aspects of Diabetes Research and Therapeutic Development
Satin, L. S., Soleimanpour, S. A., & Walker, E. M. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000160 · Cited by 34
Pancreatic β cell regeneration induced by clinical and preclinical agents
Wang, K., Tao, M., Wei, T., & Wei, R. (2021) · World Journal of Stem Cells · doi:10.4252/wjsc.v13.i1.64 · Cited by 30
Mokhlesi, B., Tjaden, A. H., Temple, K. A., Edelstein, S. L., Sam, S., Nadeau, K. J., Hannon, T. S., Manchanda, S., Mather, K. J., Kahn, S. E., et al. (2021) · Diabetes Care · doi:10.2337/dc20-2127 · Cited by 29
“We performed a cross-sectional analysis of data obtained during the run-in and baseline phases of the RISE Adult Medication Study (10).”
BackgroundInfluentialSelf-citationStructural Lesions on Kidney Biopsy in Youth-Onset and Adult-Onset Type 2 Diabetes
Looker, H. C., Pyle, L., Vigers, T., Severn, C., Saulnier, P., Najafian, B., Mauer, M. S., Nelson, R. G., & Bjornstad, P. (2022) · Diabetes Care · doi:10.2337/dc21-1688 · Cited by 24
Type 2 Diabetes Mellitus in Childhood and Adolescence
Koren, D., & Levitsky, L. L. (2021) · Pediatrics in Review · doi:10.1542/pir.2019-0236 · Cited by 25
Retnakaran, R. R., Ye, C., Emery, A., Kramer, C. K., & Zinman, B. (2022) · Nature Communications · doi:10.1038/s41467-022-33867-9 · Cited by 22
Retnakaran, R. R., Emery, A., Ye, C., Harris, S. B., Reichert, S. M., McInnes, N., Gerstein, H. C., Thorpe, K. E., Kramer, C. K., & Zinman, B. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14421 · Cited by 22
Zeng, J., Gan, S., Mi, N., Liu, Y., Su, X., Zhang, W., Zhang, J., Yu, F. H. Z., Dong, X., Han, M., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15179 · Cited by 22
Increased β-Cell Responsivity Independent of Insulin Sensitivity in Healthy African American Adults
Armiyaw, L., Sarcone, C., Fosam, A. E., & Muniyappa, R. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa234 · Cited by 18
Ryder, J. R., Xu, P., Nadeau, K. J., Kelsey, M. M., Xie, C., Jenkins, T. M., Inge, T. H., & Bjornstad, P. (2020) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2020.09.002 · Cited by 20
“Further compounding the issue, pharmacotherapy may have different effects in youth-onset versus adult-onset T2D as illustrated in the recently completed Restoring Insulin Secretion (RISE) study [7,27,28].”
BackgroundSelf-citationTommerdahl, K. L., Kendrick, J., Nelson, R. G., & Bjornstad, P. (2022) · Clinical Science · doi:10.1042/cs20210627 · Cited by 19
Contemporary Clinical Perspectives on Targeting Remission of Type 2 Diabetes
Retnakaran, R. R., Kashyap, S. R., Gerstein, H. C., & Aroda, V. R. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad746 · Cited by 19
Razzaki, T. S., Weiner, A., & Shukla, A. P. (2022) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s328056 · Cited by 16
“The three treatment arms resulted in improvement in glucose-stimulated insulin secretion, which was most apparent in the liraglutidemetformin group, though the effect dissipated within 3 months of treatment cessation.(10) In a 3-year study on subjects with prediabetes with a BMI ≥30 kg/m(2) or ≥27 kg/m(2) with hyperte…”
Jiang, Y., Wang, L., Dong, Z., Xia, B., & Pang, S. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.13563 · Cited by 12
“78 Therefore, new antidiabetic drugs are urgently needed.”
BackgroundZhang, B., Zhang, X., Luo, Z., Ren, J., Yu, X., Zhao, H., Wang, Y., Zhang, W., Wei-wei, T., Wei, X., et al. (2023) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2023.08.005 · Cited by 17
Beta‐cell function in type 2 diabetes ( T2DM ): Can it be preserved or enhanced?
Kassem, L. S., Rajpal, A., Barreiro, M. V. E., & Ismail‐Beigi, F. (2023) · Journal of Diabetes · doi:10.1111/1753-0407.13446 · Cited by 16
“136 Le Roux et al showed that the larger dose of liraglutide (3 mg daily) used for 3 years in patients with prediabetes was associated with an improvement in beta-cell function.”
BackgroundMethodShould Prediabetes be Treated Pharmacologically?
Davidson, M. B. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01449-7 · Cited by 13
Rosenstock, J., Robins, D. A., Duffin, K. L., Wilson, J. M., Lin, Y., Banerjee, H., Eyde, S., KAZDA, C. M., Кониг, М., & Mather, K. J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70022 · Cited by 13
Self-citationGlucokinase and glucokinase activator
Li, C., Zhang, Y., Chen, L., & Li, X. (2023) · Life Metabolism · doi:10.1093/lifemeta/load031 · Cited by 10
Insulin Dynamics and Pathophysiology in Youth-Onset Type 2 Diabetes
Abu-Nejem, R., & Hannon, T. S. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae463 · Cited by 8
Self-citationFurther RISE’ing to the Challenge of Type 2 Diabetes in Youth
Klein, K. R., & Buse, J. B. (2021) · Diabetes Care · doi:10.2337/dci21-0023 · Cited by 8
“of washout from medical intervention (10).”
Gurlo, T., Prakash, T. P., Wang, Z., Archang, M. M., Pei, L., Rosenberger, M., PIRIE, E. C., Lee, R. G., & Butler, P. C. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1096286 · Cited by 5
“Of note, while GLP-1 agonist treatment delays diabetes in numerous rodent models of diabetes, this benefit does not extend to humans (Young et al., 1999; Moffett et al., 2015; Fan et al., 2018; Consortium, 2019).”
BackgroundPrecision and accuracy of hyperglycemic clamps in a multicenter study
Mather, K. J., Tjaden, A. H., Hoehn, A., Nadeau, K. J., Buchanan, T. A., Kahn, S. E., Arslanian, S. A., Caprio, S., Atkinson, K. M., Cree‐Green, M., et al. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00598.2020 · Cited by 5
Self-citationWen, W., Huang, H., Lin, H.-C., Lo, W., Chen, S., & Lee, M. (2022) · Nutrients · doi:10.3390/nu14020320 · Cited by 5
Intervention with Therapeutic Agents, Understanding the Path to Remission to Type 2 Diabetes
Hao, S., Umpierrez, G. E., & Vellanki, P. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.07.004 · Cited by 6
Novel Approaches to Restore Pancreatic Beta-Cell Mass and Function
Welters, A., & Lammert, E. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_474 · Cited by 5
Kahn, S. E., Edelstein, S. L., Arslanian, S. A., Barengolts, E., Caprio, S., Ehrmann, D. A., Hannon, T. S., Marcovina, S. M., Mather, K. J., Nadeau, K. J., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0461 · Cited by 6
Self-citationBruhn, L., Vistisen, D., Vainø, C. T. R., Perreault, L., & Færch, K. (2020) · Endocrine · doi:10.1007/s12020-020-02234-3 · Cited by 4
“Defective beta-cell function is not easily restored by drug therapy aimed at providing beta-cell rest [32, 33].”
BackgroundReflections on the state of diabetes research and prospects for treatment
Accili, D., Du, W. J., Kitamoto, T., Kuo, T., McKimpson, W. M., Miyachi, Y., Mukhanova, M., Son, J., Wang, L., & Watanabe, H. (2022) · Diabetology International · doi:10.1007/s13340-022-00600-2 · Cited by 5
A Gut-Centric Model of Metabolic Homeostasis
Rajagopalan, H., López-Talavera, J. C., Klonoff, D. C., & Cherrington, A. D. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211044523 · Cited by 5
Lee, C. J., Bergman, B. K., Gou, R. Y., WILLIAMSON, S. E., & Boye, K. S. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01788-7 · Cited by 7
Middleton, T. L., Constantino, M. I., McGill, M., D’Souza, M., Yue, D. K., Twigg, S. M., Wu, T., & Wong, J. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14621 · Cited by 2
“treatment in youth followed by metformin nor early use of liraglutide and metformin alone in adults attenuated progressive functional β-cell decline.(4,16) Clearly, greater durability of glycaemic benefit and persistence of functional β-cell improvement needs to be definitively proven before any new treatment paradigm…”
BackgroundThe linearized disposition index augments understanding of treatment effects in diabetes
Kile, A. J., Hanna, C., Hannon, T. S., Kirkman, M. S., Considine, R. V., Patel, Y. R., & Mather, K. J. (2020) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00397.2020 · Cited by 2
Self-citationDíez, J. J., Anda, E., Lesmes, I. B., González, C., Miguélez, M., Zugasti, A., & Fernández, A. (2025) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2025.101531 · Cited by 4
Brèves: Préserver la sécrétion d’insuline : un défi impossible chez le diabétique de type 2 ?
Bastin, M. (2019) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(19)30176-2
Highlights from the 79th Scientific Sessions of the American Diabetes Association
Day, C. (2019) · British Journal of Diabetes · doi:10.15277/bjd.2019.232
Youth Along the T2D Risk Continuum Remain Concerningly Refractory to Therapeutic Interventions
Wolfgram, P. M., & Cabrera, S. M. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab292
Lalau, J. (2021) · Elsevier eBooks · doi:10.1016/b978-2-294-76753-1.00047-3 · Cited by 1
Utzschneider, K. M., Ehrmann, D. A., Arslanian, S. A., Barengolts, E., Buchanan, T. A., Caprio, S., Edelstein, S. L., Hannon, T. S., Kahn, S. E., Kozedub, A., et al. (2022) · Obesity · doi:10.1002/oby.23475
“data from the BetaFat Study [14] and the Adult Medication Study [15].”
BackgroundMethodSelf-citationA New Bar for Pharmacologic Weight Loss: Type 2 Diabetes Prevention
Dungan, K. M. (2022) · Diabetes Care · doi:10.2337/dci22-0019
Waili, A. H. A., Shuhoumi, M. A. A., & Turner, M. D. (2023) · Research Square · doi:10.21203/rs.3.rs-3161563/v1
Díez, J. J., Anda, E., Bretón, I., González, C., Miguélez, M., Zugasti, A., & Fernández, A. (2024) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2024.11.001 · Cited by 1
Ling, W., Wang, Y.-C., Huang, Y., Ou, Y.-X., & Jiang, Y. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v16.i2.94976 · Cited by 1
Hao, S., Westbrook, A. L., Sinha, C. B., Hsia, D. S., & Vellanki, P. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.10.001 · Cited by 1
DeLacey, S. E., Dieguez, A. C., & Bensignor, M. O. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01823-7
Liu, X., Liu, Y.-G., Lv, Y., & Deng, B. (2026) · Current Medical Science · doi:10.1007/s11596-026-00168-x
Ekinci, E. I., Maldonado, S. G., Unseld, A., Arrubla, J., Hennige, A. M., & Schoelch, C. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70861
“However, clinical studies suggest that these improvements are largely treatment-dependent and probably decrease after therapy withdrawal, indicating predominantly reversible enhancement rather than durable restoration of beta-cell function [24–27].”
Raval, K., Ilegems, E., Title, A. C., Fishburn, E., Bhardwaj, G., Mirguet, O., Ratcliffe, P. D., Greeff, O. B. W., van Wyk, A., & Tudzarova, S. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.20.752954 · Cited by 1
OGTT Early C-Peptide Index for Clamp-Measured Acute β-Cell Secretory CapacityPreprint
Zhang, R. (2026) · medRxiv · doi:10.64898/2026.10.05.26364738
Seo, B., Maretti-Mira, A. C., Wang, H., Matsuba, C., Romano, J. D., Choi, Y. J., Hampson, H. E., Salomon, M. P., Pyle, L. L., Aung, M. T., et al. (2026) · Next research. · doi:10.1016/j.nexres.2026.102607
Metadata
- Authors
- The RISE Consortium, Ehrmann, D. A., Temple, K. A., Rue, A., Barengolts, E., Mokhlesi, B., Van Cauter, E., Sam, S., Miller, M. A., Kahn, S. E., Atkinson, K. M., Palmer, J. P., Utzschneider, K. M., Gebremedhin, T., Kernan-Schloss, A., Kozedub, A., Montgomery, B. K., Morse, E. J., Mather, K. J., Garrett, T., Hannon, T. S., Lteif, A., Patel, A., Chisholm, R., Moore, K., Pirics, V., Pratt, L., Nadeau, K. J., Gross, S., Zeitler, P. S., Williams, J., Cree-Green, M., Garcia Reyes, Y., Vissat, K., Arslanian, S. A., Brown, K., Guerra, N., Porter, K., Caprio, S., Savoye, M., Pierpont, B., Buchanan, T. A., Xiang, A. H., Trigo, E., Beale, E., Chow, T., Hendee, F. N., Katkhouda, N., Nayak, K., Martinez, M., Montgomery, C., Wang, X., Wu, J., Edelstein, S. L., Lachin, J. M., Tjaden, A. H., Marcovina, S., Harting, J., Albers, J., Hill, D., Savage, P. J., & Leschek, E. W.
- ORCID
- Mokhlesi, Babak
- Kahn, Steven E.
- Atkinson, Karen M.
- Utzschneider, Kristina M.
- Mather, Kieren J.
- Hannon, Tamara S.
- Nadeau, Kristen J.
- Zeitler, Philip S.
- Arslanian, Silva A.
- Caprio, Sonia
- Buchanan, Thomas A.
- Xiang, Anny H.
- Beale, Elizabeth
- Chow, Ting
- Martinez, Mayra
- Wang, Xinhui
- Wu, Jun
- Edelstein, Sharon L.
- Lachin, John M.
- Tjaden, Ashley Hogan
- Marcovina, Santica
- Leschek, Ellen W.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-06-09
- Volume
- 42
- Issue
- 9
- Pages
- 1742-1751
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC6702605
- OpenAlex
- W4241784903
- Cited by
- 73
- References
- 40
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 5 · 2023: 11 · 2022: 16 · 2021: 18 · 2020: 9 · 2019: 3
- FWCI
- 9.34
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (U01DK-094406, U01DK-094430, U01DK-094431, U01DK-094438, U01DK-094467, P30DK-017047, P30DK-020595, P30DK-045735, P30DK-097512)
- National Center for Advancing Translational Sciences (UL1TR-000430, UL1TR-001082, UL1TR-001108, UL1TR-001855, UL1TR-001857, UL1TR-001858, UL1TR-001863)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- beta-cell function, impaired glucose tolerance, type 2 diabetes, metformin, insulin glargine, liraglutide, treatment withdrawal, hyperglycemic clamp, C-peptide response, insulin secretion
- MeSH terms
- Insulin Glargine, Liraglutide, Adult, Arginine, B-Lymphocytes, Blood Glucose, Body Weight, C-Peptide, Diabetes Mellitus, Type 2, Fasting, Female, Humans, Hypoglycemic Agents, Insulin Resistance, Male, Metformin, Middle Aged, Glucose Intolerance, Withholding Treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.